Adeno‑associated virus (AAV) vectors have become a central platform for gene therapy, enabling treatments that address disease at the genetic level rather than managing symptoms. To date, most approved AAV‑based therapies have focused on rare diseases, where patient populations are small and manufacturing volumes, while technically demanding, remain limited. That landscape is beginning to change.
As viral vector gene therapy advances toward non‑rare and prevalent diseases, the industry faces a fundamental inflection point: can AAV manufacturing scale to meet population‑level demand while maintaining capacity, consistency, and robustness? The answer will play a decisive role in whether AAV therapies can move from niche solutions to broadly accessible medicines.
Why AAV manufacturing for non rare diseases changes the equation
Treating non‑rare diseases reshapes nearly every assumption behind current adeno-associated virus manufacturing models. Larger patient populations translate directly into significantly higher vector demand, particularly for therapies delivered systemically rather than locally or ex vivo. Processes designed for rare indications often rely on smaller batch sizes, labor‑intensive workflows, or scale‑out approaches. These factors can quickly reach practical and economic limits when applied to tens or hundreds of thousands of patients.
At the same time, dosing expectations often increase as gene therapy moves beyond ultra‑rare indications. Higher dosing requirements compound pressure on manufacturing systems, driving the need for more efficient production and more predictable scale‑up. For non‑rare diseases, manufacturing (Fig 1) becomes not just a technical necessity but a gatekeeper to patient access.
Fig 1. From research and development to fill and finish, the manufacturing process for AAV includes many steps that must be adjusted for large-scale AAV production.
Capacity: how much do we need and how quickly can we make it?
One of the most pressing AAV gene therapy manufacturing challenges is capacity. Much of the existing AAV manufacturing infrastructure was built to support early clinical programs and rare‑disease commercialization. As pipelines mature and indications expand, that infrastructure risks becoming a bottleneck.
Scalable AAV production capacity challenges are not solely a matter of physical footprint. Decisions made early in development, such as cell lines, cell culture format, upstream production strategy, and facility design, can either enable or constrain future scale‑up. Simply replicating small‑scale systems may increase output incrementally, but it often brings diminishing returns in labor efficiency, cost, and operational complexity.
For non‑rare diseases, the central question is no longer “Can we make AAV?” but “Can our manufacturing strategy scale quickly and sustainably to meet real‑world demand?”
Consistency: reproducibility at population scale
As manufacturing volumes rise, consistency becomes both harder to achieve and more critical to maintain. Viral vectors are inherently more complex than many traditional biologics. That complexity increases sensitivity to process variation. Minor changes in upstream conditions, raw materials, or downstream handling can introduce variability that becomes amplified at scale.
For therapies targeting non‑rare diseases, consistency is not just a regulatory requirement; it is a clinical and commercial imperative. Large patient populations depend on reproducible product quality across many batches, sites, and time horizons. Manufacturing approaches that lack built‑in consistency risk increased comparability exercises, regulatory scrutiny, and supply disruptions.
The need for consistency raises important questions across the industry:
- How early should processes be designed with commercial‑scale in mind?
- Which platforms best maintain performance as batch size and throughput increase?
- How can variability be minimized before it becomes entrenched?
At large scale, consistency becomes synonymous with confidence in the product, the process, and the supply chain.
Robustness: manufacturing that withstands pressure
Closely linked to consistency is robustness: the ability of a manufacturing process to perform reliably under operational stress. For non‑rare diseases, robustness takes on heightened importance because the consequences of failure scale along with production volume. A single deviation can affect thousands of doses, delay treatment, and strain healthcare systems.
Robust processes are those designed to tolerate variation without constant intervention. They rely on closed, automated systems where possible, minimize manual handling, and avoid late‑stage process changes that trigger complex regulatory work. Designing robustness into manufacturing is not an optimization step. It is a foundational requirement for population‑scale therapy.
As demand grows, the industry must ask:
- Which processes can endure sustained, high‑volume operation?
- How resilient are current manufacturing models to scaling pressure?
- Where are the hidden fragilities that only emerge at large scale?
Manufacturing strategy as a determinant of access
Taken together, capacity, consistency, and robustness form the core of large‑scale AAV manufacturing strategy. For non‑rare diseases, these factors increasingly determine not just how therapies are made, but whether they can be made at all for broad patient populations.
Manufacturing is no longer a downstream consideration to be optimized after clinical success. It is a parallel development path that shapes timelines, costs, regulatory pathways, and ultimately patient reach. As AAV‑based therapies move beyond rare diseases, manufacturing readiness becomes inseparable from therapeutic potential.
Conclusion: scaling the science to scale the impact
The science of AAV gene therapy has advanced rapidly. Manufacturing must now evolve with equal urgency. For non‑rare diseases, success will depend on building scalable, consistent, and robust manufacturing strategies that support sustained production without compromising quality or reliability.
The next chapter of AAV gene therapy will not be written by scientific innovation alone. It will be defined by the industry’s ability to translate that innovation into manufacturing systems capable of delivering gene therapies to many; not just a few.